With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer for Recovery Centers of America, told Cocaine, Meth & Stimulant Summit attendees in a Saturday session.